Vilya, Inc.vilya.aiComputational platform designing macrocyclic drugs from scratch with AI
According to AlphaMoat, in the latest data month Vilya (vilya.ai) received 0 monthly visits — ranked #0 of 17,407 AI websites with traffic data, and #0 of 3,173 in Industry Services.
Monthly Visits
-
Overall Rank (17,407)
-
Industry Services Rank (3,173)
-
Top Market
-
What is Vilya
Product Overview
Vilya uses computation-driven drug design to create macrocyclic molecules that do not exist in nature—combining the selectivity of biologics with the convenience of oral pills—to tackle previously hard-to-treat diseases. The company grew out of Nobel Prize-level research from the Institute for Protein Design, with scientific founder David Baker winning the 2024 Nobel Prize in Chemistry.
Key Features3 items
- 01The platform generates, predicts, and validates entirely new macrocyclic molecules in silico, designing therapeutic molecules at atomic precision
- 02it advances an oral, permeable drug pipeline whose progress page shows Oncology Target A at 50% complete, integrin alpha4beta7 (inflammatory bowel disease) at 83.33%, and Immunology Targets C and D each at 33.33%
- 03it has released two generations of all-atom foundation models, Vilya-1 and Vilya-2, for macrocyclic structure-prediction design and chemically diverse molecular interface modeling
Popular in Industry Services
Click for details, or "+ Compare" to compare with Vilya
Data month: — · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.